Ossiform
Ossiform develops bioactive bone substitutes that provide structure and consistency while facilitating the natural forming of new bone. The company 3D prints bone substitutes from beta-tricalcium phosphate with indication-specific biomechanical considerations to support bone healing and simplify complex procedures. Ossiform's technology enables surgeons to reconstruct bone without the risks of permanent foreign body…
Funding snapshot
About
Ossiform develops bioactive bone substitutes that provide structure and consistency while facilitating the natural forming of new bone. The company 3D prints bone substitutes from beta-tricalcium phosphate with indication-specific biomechanical considerations to support bone healing and simplify complex procedures. Ossiform's technology enables surgeons to reconstruct bone without the risks of permanent foreign body implantation or the inherent variability of allografts. The bio-integrative material remodels into new vascularized bone with balanced resorption rates, offering controlled cortical and cancellous components. ISO 13485 certified, Ossiform also offers a research line of bioceramic bone-mimicking scaffolds for cell and bacteria studies, tissue engineering, disease modeling, and drug screening as an animal-free alternative. Founded in 2017, headquartered in Odense, Denmark, The company has raised $20.6M at the Series B stage, backed by investors including Asimov Ventures, West Hill Capital, Nordic Startup Awards, Innovationsfonden, moabiotech.com..
Business model
3D Printing > Applications > Healthcare > Orthopedics,
Orthopedics > Medical Devices > Therapies > Regenerative medicine,
Life Sciences Platforms and Tools > Instruments > 3D Bioprinting
Founders & team highlights
Serial Founder
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.